



LIPID-DRUG CONJUGATES

Innovation and Applications

Edited by
Malay K. Das



Academic Press is an imprint of Elsevier
125 London Wall, London EC2Y 5AS, United Kingdom
525 B Street, Suite 1650, San Diego, CA 92101, United States
50 Hampshire Street, 5th Floor, Cambridge, MA 02139, United States

Copyright © 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

For accessibility purposes, images in electronic versions of this book are accompanied by alt text descriptions provided by Elsevier. For more information, see <https://www.elsevier.com/about/accessibility>.

Publisher's note: Elsevier takes a neutral position with respect to territorial disputes or jurisdictional claims in its published content, including in maps and institutional affiliations.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions.

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

Notices

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

ISBN: 978-0-443-33382-8

For Information on all Academic Press publications
visit our website at <https://www.elsevier.com/books-and-journals>

Publisher: Stacy Masucci
Acquisitions Editor: Andre Wolff
Editorial Project Manager: Namrata Lama
Production Project Manager: Selvaraj Raviraj
Cover Designer: Vicky Pearson Esser

Typeset by MPS Limited, Chennai, India



Contents

| | |
|----------------------------|-----|
| List of contributors | xv |
| Preface | xix |

PART 1 Innovations in lipid-drug conjugates

| | |
|---|----------|
| CHAPTER 1 Lipid-drug conjugates: application of lipid in drug delivery | 3 |
| <i>Bhriyumani Kalita, Parismita Sonowal and Malay K. Das</i> | |
| 1.1 Introduction | 3 |
| 1.2 The concept of lipid-drug conjugates | 6 |
| 1.3 Various lipid moieties used in lipid-drug conjugate designing | 7 |
| 1.3.1 Fatty acids | 7 |
| 1.3.2 Glycerides..... | 7 |
| 1.3.3 Phospholipids | 8 |
| 1.3.4 Steroids..... | 8 |
| 1.3.5 Fat-soluble endogenous molecules | 9 |
| 1.4 Method of preparation..... | 9 |
| 1.4.1 Lipid-drug conjugates with noncovalent linkages | 9 |
| 1.4.2 Lipid-drug conjugates with covalent linkages: without spacer | 12 |
| 1.4.3 Lipid-drug conjugates with covalent linkages: with spacer..... | 14 |
| 1.5 Incorporation of lipid-drug conjugates in delivery systems..... | 15 |
| 1.5.1 High-pressure homogenization | 15 |
| 1.5.2 Microemulsion technique..... | 16 |
| 1.5.3 Solvent emulsification evaporation | 16 |
| 1.5.4 Solvent emulsification–diffusion | 16 |
| 1.6 Delivery system for lipid-drug conjugates | 16 |
| 1.6.1 Liposomes | 16 |
| 1.6.2 Emulsions | 17 |
| 1.6.3 Micelles | 17 |
| 1.6.4 Lipid nanoparticles..... | 18 |
| 1.6.5 Polymeric nanoparticles | 18 |
| 1.7 Advantages of lipid-drug conjugates | 19 |
| 1.7.1 Targeted drug delivery..... | 19 |
| 1.7.2 Enhancement of oral bioavailability..... | 19 |
| 1.7.3 Overcoming drug resistance | 20 |
| 1.7.4 Achieving extended drug release..... | 20 |
| 1.7.5 Enhance tumor targeting and reduce toxicity | 20 |

| | | |
|---|---|----|
| 1.8 | Applications of lipid-drug conjugates..... | 21 |
| 1.9 | Conclusion and future perspective..... | 22 |
| | References..... | 22 |
| CHAPTER 2 Lipid-drug conjugates: conjugation methods and therapeutic benefits..... 29 | | |
| <i>L. Ronibala Singha, Sentu Das and Malay K. Das</i> | | |
| 2.1 | Introduction | 29 |
| 2.2 | Lipid-drug conjugation methods..... | 30 |
| 2.2.1 | Lipid-drug conjugates with covalent bonds | 30 |
| 2.2.2 | Lipid-drug conjugates with non-covalent bonds..... | 34 |
| 2.3 | Therapeutic benefits of lipid-drug conjugates..... | 35 |
| 2.3.1 | Low-density lipoproteins-assisted targeted drug delivery | 35 |
| 2.3.2 | Low-density lipoproteins-assisted tumor targeting and reduce toxicity | 35 |
| 2.3.3 | Low-density lipoproteins for countering drug resistance..... | 37 |
| 2.3.4 | Low-density lipoproteins for oral drug bioavailability enhancement..... | 37 |
| 2.3.5 | Low-density lipoproteins for boosting pharmacological activity | 42 |
| 2.4 | Current status quo on clinical trials of lipid-drug conjugates..... | 42 |
| 2.5 | Conclusion and future perspectives | 43 |
| | References..... | 43 |
| | Further reading | 49 |
| CHAPTER 3 Route of administration and cellular interaction of lipid drug conjugates 51 | | |
| <i>Taison Jamatia, Rishav Mazumder, Ichudaule, Swarnali Sonowal and Malay K. Das</i> | | |
| 3.1 | Introduction | 51 |
| 3.2 | Delivery system of lipid drug conjugations | 52 |
| 3.2.1 | Emulsion..... | 52 |
| 3.2.2 | Liposomes | 54 |
| 3.2.3 | Micelles | 55 |
| 3.2.4 | Lipid nanoparticles..... | 55 |
| 3.2.5 | Polymeric nanoparticles..... | 56 |
| 3.3 | Routes of administration | 57 |
| 3.3.1 | Oral..... | 57 |
| 3.3.2 | Intravenous | 60 |
| 3.3.3 | Subcutaneous..... | 62 |
| 3.4 | Cellular interaction of lipid drug conjugates..... | 64 |
| 3.4.1 | Cellular uptake by interacting with lipids | 64 |

| | |
|---|-----------|
| 3.4.2 Cellular uptake by interacting with proteins in cell membrane | 65 |
| 3.4.3 Cellular uptake of saccharides located in cell membrane | 66 |
| 3.4.4 Through disulfide exchange..... | 66 |
| 3.5 Conclusion | 66 |
| References..... | 67 |
| | |
| CHAPTER 4 Lipid–drug conjugates for enhanced drug delivery and targeting | 77 |
| <i>Nayan Ranjan Ghose Bishwas and Malay K. Das</i> | |
| 4.1 Introduction | 77 |
| 4.2 Lipid–drug conjugate | 78 |
| 4.3 Selection of drugs, lipids, solvents, and possible linkers in the formulation of lipid–drug conjugates | 80 |
| 4.4 Application of lipid–drug conjugates: a flourishing approach for enhanced drug targeting | 81 |
| 4.4.1 Enhancing oral drug delivery | 81 |
| 4.4.2 Improve the delivery of anticancer drugs..... | 82 |
| 4.4.3 Overcoming drug resistance | 83 |
| 4.4.4 Enhancing central nervous system drug delivery with lipid–drug conjugates..... | 84 |
| 4.4.5 Enhancing delivery of gene medicines with lipid–drug conjugates..... | 84 |
| 4.5 Mechanism of drug release from lipid–drug conjugates | 87 |
| 4.5.1 pH-responsive lipid–drug conjugates | 88 |
| 4.5.2 Enzyme-responsive lipid–drug conjugates..... | 88 |
| 4.5.3 Redox-responsive lipid–drug conjugates..... | 89 |
| 4.5.4 Reactive oxygen species-responsive lipid–drug conjugates | 89 |
| 4.6 Conclusion and future perspectives | 90 |
| Acknowledgment | 91 |
| Conflict of interest..... | 91 |
| References..... | 91 |
| Further reading | 94 |
| | |
| CHAPTER 5 Antibody-conjugated lipid nanoparticles as a targeted drug delivery system for hydrophobic drugs | 97 |
| <i>Sawant Akash Govardhan, Sneha Balki, Ekta Swarnamayee Panda, Paul Gajanan Balaji, Avtar Singh Gautam, Awesh Kumar Yadav and Rakesh Kumar Singh</i> | |
| 5.1 Introduction | 97 |
| 5.2 Hydrophobic drugs and their delivery challenges | 98 |
| 5.2.1 Techniques for solubility enhancement of hydrophobic drugs..... | 99 |

| | | |
|------------------|---|------------|
| 5.3 | Lipid nanoparticles, and antibodies as targeting agents..... | 99 |
| 5.3.1 | Liposome..... | 101 |
| 5.3.2 | Solid lipid nanoparticles..... | 102 |
| 5.3.3 | Nanostructured lipid carriers..... | 103 |
| 5.3.4 | Lipid–polymer hybrid nanoparticles..... | 104 |
| 5.3.5 | Nanoemulsions..... | 104 |
| 5.3.6 | Lipid drug conjugates nanoparticles..... | 105 |
| 5.3.7 | Transferosomes..... | 105 |
| 5.4 | Antibodies as targeting agents..... | 105 |
| 5.4.1 | Overview of antibody structure and function..... | 105 |
| 5.4.2 | Design for antibody-targeted nanoparticles..... | 107 |
| 5.5 | Conjugation techniques for ACNP production..... | 108 |
| 5.5.1 | Adsorption..... | 109 |
| 5.5.2 | Binding by adapter molecules..... | 109 |
| 5.5.3 | Covalent strategies..... | 110 |
| 5.5.4 | Carbodiimide chemistry..... | 111 |
| 5.5.5 | Maleimide chemistry..... | 111 |
| 5.5.6 | Click chemistry..... | 112 |
| 5.5.7 | Multivalent effect of antibody-conjugated nanoparticles..... | 112 |
| 5.6 | Challenges in the development of ACNPs for medical use..... | 113 |
| 5.7 | Diagnostic applications of ACNPs..... | 113 |
| 5.7.1 | In vitro diagnostic applications..... | 114 |
| 5.7.2 | In vivo diagnostic applications..... | 115 |
| 5.8 | Future perspectives..... | 118 |
| 5.9 | Conclusion..... | 119 |
| | Author contributions..... | 119 |
| | Declaration of competing interest..... | 120 |
| | Acknowledgments..... | 120 |
| | References..... | 120 |
| CHAPTER 6 | Pharmacokinetics of lipid drug conjugates..... | 137 |
| | <i>Probin Kumar Roy, Anima Debbarma, Magdalini Tarai, Pratap Kalita, Malay K. Das and Lalduhsanga Pachuau</i> | |
| 6.1 | Introduction..... | 137 |
| 6.2 | Structural features, conjugation methods, and delivery carriers..... | 138 |
| 6.2.1 | Different types of conjugation strategies..... | 138 |
| 6.3 | Pharmacokinetics of lipid drug conjugates..... | 140 |
| 6.3.1 | Absorption and permeation..... | 141 |
| 6.3.2 | Distribution..... | 144 |
| 6.3.3 | Metabolism..... | 148 |

| | |
|--|-----|
| 6.3.4 Clearance and elimination of lipid drug conjugates | 149 |
| 6.4 Clinical implications of lipid drug conjugates and its challenges | 150 |
| 6.5 Conclusion and future directions | 152 |
| References..... | 153 |

| | | |
|------------------|---|------------|
| CHAPTER 7 | Production and characterization of various delivery carriers for lipid–drug conjugates | 161 |
| | <i>Punamjyoti Das and Malay K. Das</i> | |
| 7.1 | Introduction | 161 |
| 7.2 | Delivery carries of lipid–drug conjugates | 163 |
| 7.2.1 | Emulsion..... | 164 |
| 7.2.2 | Liposome..... | 164 |
| 7.2.3 | Niosome | 164 |
| 7.2.4 | Polymeric nanoparticles..... | 165 |
| 7.2.5 | Polymeric micelles..... | 165 |
| 7.2.6 | Solid lipid nanoparticle..... | 166 |
| 7.2.7 | Nanostructured-lipid carrier..... | 166 |
| 7.2.8 | Carbon nanotubes..... | 166 |
| 7.2.9 | Mesoporous silica nanoparticle | 167 |
| 7.3 | Production method of lipid–drug conjugate loaded delivery carriers | 167 |
| 7.3.1 | High pressure homogenization | 167 |
| 7.3.2 | Microemulsion technique..... | 168 |
| 7.3.3 | Solvent emulsification–evaporation | 168 |
| 7.3.4 | Solvent emulsification–diffusion..... | 168 |
| 7.3.5 | Solvent injection | 169 |
| 7.3.6 | Thin film hydration..... | 169 |
| 7.3.7 | Wet milling | 169 |
| 7.4 | Characterization of lipid–drug conjugates loaded delivery carrier..... | 169 |
| 7.4.1 | Fourier transformed infrared spectra analysis | 169 |
| 7.4.2 | Mass spectroscopy | 172 |
| 7.4.3 | Nuclear magnetic resonance | 172 |
| 7.4.4 | Particle size | 172 |
| 7.4.5 | Polydispersity index | 172 |
| 7.4.6 | Zeta potential | 173 |
| 7.4.7 | Electron microscopy analysis | 173 |
| 7.4.8 | Crystal structure study | 173 |
| 7.4.9 | Fluorescence spectroscopy..... | 174 |
| 7.4.10 | Entrapment efficiency and drug loading | 174 |
| 7.4.11 | In vitro drug release and release kinetic assessment | 174 |
| 7.4.12 | Stability testing | 175 |

| | | |
|-----|---|-----|
| 7.5 | Mechanism of drug release from lipid–drug conjugates based carriers | 175 |
| 7.6 | Clinical aspects of lipid–drug conjugates based drug development | 177 |
| 7.7 | Patent review on lipid–drug conjugates | 178 |
| 7.8 | Regulatory aspects of lipid–drug conjugate nanocarriers | 179 |
| 7.9 | Conclusion | 180 |
| | References | 181 |

PART 2 Applications of lipid-drug conjugates

CHAPTER 8 Lipid-drug conjugates for cancer chemotherapy 191

Trideep Saikia, Bhanu P. Sahu and Malay K. Das

| | | |
|-------|---|-----|
| 8.1 | Overview of lipid-drug conjugates in cancer chemotherapy | 191 |
| 8.2 | Chemistry of lipid-drug conjugates | 192 |
| 8.2.1 | Conjugation strategies | 192 |
| 8.2.2 | Mechanism of action | 197 |
| 8.2.3 | Chemical bonds used in lipid drug conjugation | 199 |
| 8.3 | Benefits of lipid-drug conjugate over traditional chemotherapy agents | 201 |
| 8.4 | Delivery systems for lipid-drug conjugates | 202 |
| 8.4.1 | Carrier-free system | 202 |
| 8.4.2 | Emulsions | 203 |
| 8.4.3 | Liposomes | 204 |
| 8.4.4 | Micelles | 204 |
| 8.4.5 | Lipid nanoparticles | 205 |
| 8.4.6 | Polymeric nanoparticles | 206 |
| 8.5 | Stimuli-responsive lipid-drug conjugates | 207 |
| 8.6 | Current status of lipid-drug conjugates in clinical trials | 208 |
| 8.7 | Conclusion | 210 |
| | References | 210 |

CHAPTER 9 Lipid-drug conjugates for enhanced antiretroviral efficacy 221

Tapash Chakraborty, Anupam Sarma, Shatabdi Ghose and Malay K. Das

| | | |
|-------|--|-----|
| 9.1 | Introduction | 221 |
| 9.2 | Principles and mechanisms of lipid-drug conjugates | 223 |
| 9.2.1 | Improved solubility and stability | 223 |
| 9.2.2 | Improved bioavailability | 223 |
| 9.2.3 | Targeted delivery | 224 |
| 9.2.4 | Sustained release | 224 |
| 9.2.5 | Improved pharmacokinetics | 225 |

| | | |
|------------|---|------------|
| 9.2.6 | Improved cellular uptake | 225 |
| 9.2.7 | Combination therapy..... | 226 |
| 9.2.8 | Tailored formulation design | 226 |
| 9.3 | Preclinical studies and in vitro evaluation..... | 227 |
| 9.3.1 | In vitro evaluation..... | 227 |
| 9.3.2 | Preclinical in vivo studies..... | 227 |
| 9.4 | Clinical studies and translational research | 229 |
| 9.4.1 | Clinical trials of lipid-drug conjugates..... | 229 |
| 9.4.2 | Translational research for lipid-drug conjugates..... | 229 |
| 9.5 | Future directions and challenges..... | 230 |
| 9.5.1 | Challenges in lipid-drug conjugate development..... | 230 |
| 9.5.2 | Future directions in lipid-drug conjugate development | 230 |
| 9.6 | Conclusion | 231 |
| | References..... | 231 |

| | | |
|-------------------|--|------------|
| CHAPTER 10 | Nano lipid-drug conjugates for the treatment of Alzheimer's disease | 237 |
| | <i>Subhajit Mandal and Malay K. Das</i> | |
| 10.1 | Introduction | 237 |
| 10.2 | Nanotechnology in the treatment of Alzheimer's disease | 239 |
| 10.2.1 | Polymeric nanoparticles..... | 239 |
| 10.2.2 | Solid lipid nanoparticles | 242 |
| 10.2.3 | Liposomes | 245 |
| 10.2.4 | Dendrimers..... | 249 |
| 10.2.5 | Nanoemulsions..... | 255 |
| 10.2.6 | Metallic nanoparticles..... | 257 |
| 10.2.7 | Carbon nanotubes..... | 261 |
| 10.3 | Nano lipid-drug conjugates..... | 263 |
| 10.3.1 | Successful treatment of Alzheimer's disease using nano lipid-drug conjugates..... | 268 |
| 10.4 | Applications of nano lipid-drug conjugates in Alzheimer's disease | 268 |
| 10.4.1 | Targeting amyloid-beta plaques | 268 |
| 10.4.2 | Blood–brain barrier penetration..... | 269 |
| 10.4.3 | Enhanced stability and bioavailability | 270 |
| 10.5 | Preclinical and clinical evidences of nano lipid-drug conjugates in the treatment of Alzheimer's disease..... | 271 |
| 10.6 | Safety and toxicity considerations | 271 |
| 10.7 | Conclusion and future perspectives | 274 |
| | References..... | 274 |

| | |
|--|------------|
| CHAPTER 11 Lipid-drug conjugates for the treatment of glioblastomas | 293 |
| <i>Anas Islam, Ambareen Fatima Ahmed, Malay K. Das, Mohsin Wahid Khan, Muskan Gupta, Sumel Ashique, Shriyansh Srivastava and Subhajit Mandal</i> | |
| 11.1 Introduction | 294 |
| 11.1.1 Overview of glioblastoma..... | 294 |
| 11.1.2 Rationale for lipid-drug conjugates in glioblastoma multiforme treatment..... | 296 |
| 11.2 Conventional chemotherapy for glioblastoma multiforme | 298 |
| 11.2.1 Current standard of care | 299 |
| 11.2.2 Limitations and challenges | 302 |
| 11.2.3 Impact on patient outcomes..... | 305 |
| 11.3 The significance of combination therapy as a promising approach against glioblastoma multiforme | 306 |
| 11.3.1 Combination therapy: a multifaceted approach | 306 |
| 11.3.2 Theoretical basis for combination therapy | 306 |
| 11.3.3 Examples of combination therapies..... | 307 |
| 11.3.4 Recent advances and innovations | 308 |
| 11.4 Progression in glioblastoma multiforme by use of nanocarriers | 309 |
| 11.4.1 Nanotechnology in glioblastoma multiforme treatment | 309 |
| 11.4.2 Types of nanocarriers..... | 310 |
| 11.4.3 Lipid-drug conjugates: a subclass of nanocarriers | 311 |
| 11.4.4 Composition and design..... | 311 |
| 11.4.5 Mechanisms of action | 312 |
| 11.4.6 Advantages over traditional therapies | 313 |
| 11.5 Challenges associated with combination drugs | 314 |
| 11.5.1 Pharmacokinetic and pharmacodynamic considerations..... | 314 |
| 11.5.2 Regulatory and developmental hurdles | 315 |
| 11.5.3 Patient-specific challenges..... | 316 |
| 11.6 Clinical trials | 317 |
| 11.6.1 Current landscape of clinical trials for glioblastoma multiforme..... | 317 |
| 11.6.2 Lipid-drug conjugate-specific trials..... | 318 |
| 11.6.3 Future directions and unmet needs..... | 319 |
| 11.7 Conclusion..... | 321 |
| References..... | 321 |
| Further reading | 332 |
| | |
| CHAPTER 12 Antibody drug conjugates integrated with lipid nanocarrier for cancer theranostics | 333 |
| <i>Boga Vijay Kumar, Anitya Shukla, Nazeer Ahmed, Krishna Solanki, Nidhi Srivastava, Shubhini A. Saraf and Niranjana Meher</i> | |
| 12.1 Introduction | 333 |

| | | |
|-------------------|--|------------|
| 12.2 | Structure-activity of antibody-drug conjugate..... | 335 |
| 12.2.1 | Structure of antibody-drug conjugate..... | 335 |
| 12.2.2 | Mechanism of action of an antibody-drug conjugates..... | 336 |
| 12.2.3 | Drug-antibody ratio..... | 337 |
| 12.3 | Various types of lipid nanocarriers..... | 337 |
| 12.3.1 | Liquid lipid nanoparticles..... | 337 |
| 12.3.2 | Solid lipid nanoparticles..... | 338 |
| 12.3.3 | Nanostructured lipid carriers..... | 338 |
| 12.4 | Integration of antibody-drug conjugates with lipid nanocarriers..... | 339 |
| 12.4.1 | Types of drug conjugation..... | 339 |
| 12.4.2 | Antibody mediated drug conjugation..... | 339 |
| 12.5 | Antibody-drug conjugate with lipid nanocarriers in cancer therapy..... | 340 |
| 12.5.1 | Breast cancer..... | 341 |
| 12.5.2 | Prostate cancer..... | 344 |
| 12.5.3 | Lung cancer..... | 345 |
| 12.5.4 | Non-Hodgkin lymphoma..... | 347 |
| 12.5.5 | Melanoma..... | 347 |
| 12.5.6 | Esophageal adenocarcinoma..... | 350 |
| 12.5.7 | Gastric cancer..... | 350 |
| 12.5.8 | Glioblastoma..... | 353 |
| 12.5.9 | Other cancer..... | 355 |
| 12.6 | Conclusion and future perspectives..... | 358 |
| | References..... | 358 |
| | | |
| CHAPTER 13 | Antibacterial drug conjugates for bacterial diseases..... | 365 |
| | <i>Trinayan Deka and Malay K. Das</i> | |
| 13.1 | Introduction..... | 365 |
| 13.2 | Mechanisms of antibacterial drug conjugates..... | 366 |
| 13.2.1 | Antibacterial drug conjugates..... | 366 |
| 13.2.2 | Peptide–drug conjugates..... | 368 |
| 13.2.3 | Polymer–drug conjugates..... | 369 |
| 13.2.4 | Nanoparticle–drug conjugates..... | 370 |
| 13.2.5 | Other emerging platforms..... | 371 |
| 13.3 | Recent advances in antibacterial drug conjugates..... | 373 |
| 13.4 | Challenges and limitations in antibacterial drug conjugates..... | 375 |
| 13.4.1 | Stability and storage..... | 375 |
| 13.4.2 | Toxicity and immunogenicity..... | 375 |
| 13.4.3 | Drug resistance..... | 375 |
| 13.4.4 | Regulatory and manufacturing hurdles..... | 376 |

| | | |
|-------------------|---|------------|
| 13.5 | Conclusion..... | 376 |
| | References..... | 376 |
| | Further reading | 380 |
| | | |
| CHAPTER 14 | Lipid-drug conjugates: future perspectives, industry trends and global forecast..... | 383 |
| | <i>Anupam Sarma, Tapash Chakraborty, Himakshi Baruah and Malay K. Das</i> | |
| 14.1 | Introduction | 383 |
| 14.2 | Industrial feasibility of manufacturing | 387 |
| 14.2.1 | High pressure homogenization | 387 |
| 14.2.2 | Microemulsion technique..... | 388 |
| 14.2.3 | Solvent emulsification—evaporation | 388 |
| 14.2.4 | Solvent emulsification—diffusion..... | 388 |
| 14.2.5 | Solvent injection | 388 |
| 14.2.6 | Milling..... | 389 |
| 14.3 | Current industry trends on lipid-drug conjugates..... | 389 |
| 14.4 | Regulatory aspects of lipid-drug conjugates | 390 |
| 14.5 | Global forecast | 393 |
| 14.6 | Conclusion and future perspectives of lipid-drug conjugates..... | 393 |
| | References..... | 394 |
| | | |
| | Index | 399 |

List of contributors

Ambareen Fatima Ahmed

School of Pharmaceutical Sciences, Integral University, Lucknow, Uttar Pradesh, India

Nazeer Ahmed

National Institute of Pharmaceutical Education and Research,
Raebareli, Lucknow, Uttar Pradesh, India

Sumel Ashique

School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India

Paul Gajanan Balaji

Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research,
Lucknow, Uttar Pradesh, India

Sneha Balki

Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education
and Research, Lucknow, Uttar Pradesh, India

Himakshi Baruah

Advanced Drug Delivery Laboratory, Department of Pharmaceutics, School of Pharmaceutical
Sciences, Girijananda Chowdhury University, Guwahati, Assam, India; Department of
Pharmaceutics, School of Pharmacy, The Assam Kaziranga University, Jorhat, Assam, India

Tapash Chakraborty

Advanced Drug Delivery Laboratory, Department of Pharmaceutics, School of Pharmaceutical
Sciences, Girijananda Chowdhury University, Guwahati, Assam, India

Malay K. Das

Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dibrugarh
University, Dibrugarh, Assam, India

Punamjyoti Das

Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dibrugarh
University, Dibrugarh, Assam, India

Sentu Das

Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dibrugarh
University, Dibrugarh, Assam, India

Anima Debbarma

Department of Pharmacy, Regional Institute of Paramedical & Nursing
Sciences, Aizawl, Mizoram, India

Trinayan Deka

Faculty of Pharmaceutical Science, Assam down town University, Panikhaiti, Guwahati, Assam,
India

Avtar Singh Gautam

Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education
and Research, Lucknow, Uttar Pradesh, India

LIPID-DRUG CONJUGATES

Innovation and Applications

Edited by Malay K. Das

Lipid-Drug Conjugates: Innovation and Applications highlights the most recent advances and clinical applications of nano lipid-drug conjugates for enhanced drug delivery and targeting in the treatment of cancer, glioblastoma, Alzheimer's, AIDS, and bacterial diseases. In addition, various conjugation methods to prepare lipid-drug conjugates and their pharmacokinetics in vivo are explored together with the production and characterization of various delivery carriers for lipid-drug conjugates. The contents of this book provide pharmaceutical science researchers with the tools to explore targeted drug delivery leveraging the unique characteristics of lipid conjugates. Scientists in the corporate setting can benefit of the cases and techniques presented in developing new formulations and products.

Key Features

- Introduces the principles, methods, and therapeutic benefits of lipid-drug conjugates
- Summarizes recent scientific progress and novel applications of nano lipid-drug conjugates
- Provides supportive clinical evidence for several applications

About the Editor

Malay K. Das (MPharm, PhD) is a Professor of Pharmaceutics at the Department of Pharmaceutical Sciences, Dibrugarh University, India. His research interests include novel drug delivery systems, pharmaceutical nanotechnology, nanomedicine, and transdermal and targeted drug delivery systems. He has handled several major research projects sponsored by the DST, DBT, ICMR, UGC, and AICTE. He has been honored with the prestigious DBT-Biotechnology Overseas Associateship at the University of South Florida, Tampa, United States, and the DST-UKIERI Research Award in collaboration with the Institute of Pharmaceutical Sciences, King's College, London, United Kingdom. He has several publications including peer-reviewed research and review articles in various international journals, as well as chapters in various books published by international publishers.



ACADEMIC PRESS

An imprint of Elsevier
elsevier.com/books-and-journals

ISBN 978-0-443-33382-8



9 780443 333828